A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Solid Tumor, Adult · Refractory Cancer · Endometrial Carcinoma (EC) · Squamous Head and Neck Carcinoma · pMMR/MSS Adenocarcinoma of the Colon or Rectum · Cutaneous Melanoma · Non-Small Cell Lung Cancer

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • The Angeles Clinic and Research Institute, Los Angeles, California, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Kristopher Wentzel, MD)
  • HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Jason Henry, MD)
  • Yale University, New Haven, Connecticut, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Patricia LoRusso, DO)
  • Florida Cancer Specialists & Research Institute, LLC, Fort Myers, Florida, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Judy Wang, MD)
  • Community Health Network, Inc., Indianapolis, Indiana, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Bert O'Neil, MD)
  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Justin Gainor, MD)
  • Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit, Michigan, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (M. Najeeb Al Hallak, MD)
  • NYU Langone Health, New York, New York, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Janice Mehnert, MD)
  • Oregon Health & Science University, Portland, Oregon, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Shivaani Kummar, MD)
  • Verdi Oncology Tennessee, Scri Oncology Partners, Nashville, Tennessee, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Meredith Pelster, MD)
  • Oncology Consultants, P.A., Houston, Texas, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Jose Peguero, MD)
  • The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Aung Naing, MD)
  • Virginia Cancer Specialists, Fairfax, Virginia, United States

    Contact: Study coordinator (GV20 Therapeutics) · clinicaltrials@gv20tx.com
    Contact: Principal Investigator (Alexander Spira, MD)